Mutationally activated Rho GTPases in cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Rho GTPases regulate cytoskeletal dynamics and are implicated in tumorigenesis.
• Previously, Rho misregulation in cancer was attributed to overexpression or altered activity of regulatory proteins (GEFs, GAPs, GDIs).
• Rho proteins themselves were not typically found mutated in cancer.

Purpose of the Study:

• To review recent findings on activating Rho GTPase mutations in various cancer types.
• To highlight the shift in understanding Rho GTPases from misregulated molecules to direct drivers of tumorigenesis.
• To emphasize the conserved nature of these mutations and their relevance in model organisms.

Main Methods:

• Review of recent literature and next-generation tumor exome sequencing data.
• Analysis of identified point mutations in Rho GTPases across different cancer types.
• Cross-species comparison of mutation relevance using model organisms like C. elegans.

Main Results:

• Activating point mutations in Rho GTPases are identified as driver mutations in melanoma, breast, and head and neck cancers.
• The Rac1(P29L) mutation, found in human tumors, was previously identified as an activating mutation in C. elegans.
• This demonstrates the conserved role of specific Rho GTPase mutations in cancer development.

Conclusions:

• Rho GTPases are now recognized as direct mutagenic targets driving tumorigenesis.
• The conserved nature of these mutations validates the use of model organisms for cancer mechanism studies.
• These findings reposition Rho GTPases in cancer research, moving beyond their role as merely misregulated proteins.